Eradivir

West Lafayette, United States

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.

$9.8M raised

Sep 2024

Series A

Top Investors

National Science FoundationBiomedical Advanced Research and Development Authority (BARDA)Philip Low

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Eradivir raised?

Eradivir has raised $9.8M in total funding. The most recent round was Series A. The last funding was announced in September 2024.

Who are Eradivir's investors?

Eradivir's investors include National Science Foundation, Biomedical Advanced Research and Development Authority (BARDA), Philip Low.

Where is Eradivir headquartered?

Eradivir is headquartered in West Lafayette, United States.

What does Eradivir do?

Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.

What stage is Eradivir at?

Eradivir is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 23, 2024.

MLA

"Eradivir — Funding & Investors." VCBacked, September 23, 2024, https://www.vcbacked.co/company/eradivir. Accessed June 17, 2026.

APA

VCBacked. (2024). Eradivir — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/eradivir

Wikipedia (cite web)

{{cite web |title=Eradivir — Funding & Investors |url=https://www.vcbacked.co/company/eradivir |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 23, 2024.